Roy S. Herbst

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Randomized phase 3 study (MarsLight-11) evaluating IBI363 (TAK-928) versus docetaxel in patients (pts) with squamous non-small cell lung cancer (sqNSCLC) after prior chemotherapy (chemo) and immunotherapy (IO).

  Journal of Clinical Oncology · 2026-05-28

• Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC).

  Journal of Clinical Oncology · 2026-05-28

• Lung-MAP S1800E: A randomized phase II/III study of docetaxel and ramucirumab with or without cemiplimab for patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC).

  Journal of Clinical Oncology · 2026-05-28

• Immune-related adverse event severity and clinical outcomes with immune checkpoint inhibitor immunotherapy in participants with non–small cell lung cancer: Analysis of the lung MAP sub-studies S1400A, S1400I, S1400F, and S1800A.

  Journal of Clinical Oncology · 2026-05-28

• A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception

  Cancer Discovery · 2026-04-19

• Abstract CT140: Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)

  Cancer Research · 2026-04-17

• 127 Pembrolizumab Monotherapy for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (NSCLC): 10-Year Outcomes From Clinical Trials

  Lung Cancer · 2026-02-01

• Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic review

  Translational Lung Cancer Research · 2026-01-01 · 1 citations

• Navigating the Evolving Landscape of <i>EGFR</i> -Mutated NSCLC

  New England Journal of Medicine · 2025-12-26 · 2 citations

• Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis

  Targeted Oncology · 2025-11-01 · 2 citations

• Bridging the gap in lung cancer: A comprehensive global strategy for change

  European Journal of Cancer · 2025-10-25 · 1 citations

• Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer

  Nature Genetics · 2025-10-01 · 30 citations

• EP.08.46 Neoadjuvant Immunotherapy Improves Recurrence-Free Survival in Resectable Non-Small Cell Lung Cancer - a 10-Year Institutional Experience

  Journal of Thoracic Oncology · 2025-10-01

• MA11.04 Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results From the Phase 3 IMforte Study

  Journal of Thoracic Oncology · 2025-10-01

• 3208P 10-year outcomes from clinical trials of pembrolizumab (pembro) monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC)

  Annals of Oncology · 2025-09-01 · 2 citations

• 2762MO Patterns of disease progression (PD) and efficacy associated with tumour burden from the phase III IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC

  Annals of Oncology · 2025-09-01

• Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024

  Cancer · 2025-08-26 · 2 citations

• Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

  Nature Communications · 2025-08-19 · 9 citations

• Data from Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study

  2025-08-14

• Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials

  Journal of Thoracic Oncology · 2025-08-05 · 5 citations